Table 1.
Clinicopathological characteristics of the FL cases.
| Asymptomatic (N = 7) | Symptomatic (N = 13) | |
|---|---|---|
| Gender | ||
| Female | 6 (85.7%) | 9 (69.2%) |
| Male | 1 (14.3%) | 4 (30.8%) |
| Age (years) | ||
| Mean (SD) | 54.4 (17.4) | 50.2 (10.6) |
| Median [Min, Max] | 58.0 [32.0, 78.0] | 54.0 [34.0, 62.0] |
| Stage | ||
| I | 1 (14.3%) | 1 (7.7%) |
| II | 2 (28.6%) | 3 (23.1%) |
| III | 3 (42.9%) | 3 (23.1%) |
| IV | 1 (14.3%) | 6 (46.2%) |
| Ki67 Index (%) | ||
| Mean (SD) | 23.0 (2.76) | 35.5 (10.9) |
| Median [Min, Max] | 23.0 [20.0, 27.0] | 35.0 [20.0, 55.0] |
| Missing | 1 (14.3%) | 2 (15.4%) |
| LDH Level (U/l) | ||
| Mean (SD) | 201 (28.0) | 238 (101) |
| Median [Min, Max] | 205 [170, 251] | 224 [110, 518] |
| Treatment | ||
| Watch-and-Wait | 7 (100%) | 0 (0%) |
| R-Bendamustine | 0 (0%) | 3 (23.1%) |
| R-CHOP | 0 (0%) | 8 (61.5%) |
| R-CVP | 0 (0%) | 1 (7.7%) |
| R-CVP-Radiotherapy | 0 (0%) | 1 (7.7%) |
LDH, Lactate dehydrogenase.
R-Bendamustine, Rituximab-Bendamustine.
R-CHOP, Rituximab- Cyclophosphamide, Hydroxydaunomycin, Oncovin, Prednisone.
R-CVP, Rituximab- Cyclophosphamide, Vincristine Sulfate, Prednisone.